Does ImmunoGen, Inc. (IMGN) Present Much Upside ?

ImmunoGen, Inc. (NASDAQ:IMGN) is on our radar right now but there could still be some opportunities on the horizon. Now trading with a market value of 533.17M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. Everyone seems to have their own opinion of this stock. But what do the numbers really say? We think it’s a great time to take a fresh look.

ImmunoGen, Inc. (NASDAQ:IMGN) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For IMGN, the company currently has 150.34 million of cash on the books, which is offset by 15.68 million in current liabilities. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 181.38 million in total assets, balanced by 354.61 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

ImmunoGen, Inc. (IMGN) saw 23.74 million in free cash flow last quarter, representing a quarterly net change in cash of 23.77 million. Perhaps most importantly where cash movements are concerned, the company saw about 24.08 million in net operating cash flow.

ImmunoGen, Inc. (NASDAQ:IMGN) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 39.02 million in total revenues. That represents a quarterly year/year change in revenues of 4.27 in sequential terms, the IMGN saw sales decline by 0.37.

But what about the bottom line? After all, that’s what really matters in the end. ImmunoGen, Inc. (IMGN) is intriguing when broken down to its core data.  For shareholders, given the total diluted outstanding shares of 87.17 million, this means overall earnings per share of -0.10. Note, this compares with a consensus analyst forecast of -0.27 in earnings per share for its next fiscal quarterly report.

Is ImmunoGen, Inc. (NASDAQ:IMGN) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -1.42 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on ImmunoGen, Inc..

Previous ArticleNext Article

Related Post

What Recent Ownership Trends Suggest About KeyCorp... Recent insider trends for KeyCorp (NYSE:KEY) have caught the attention of investors. Patters in insider activity can help analysts formulate an outloo...
Dissecting the Numbers for American Airlines Group... American Airlines Group Inc. (NASDAQ:AAL) shares are down more than -10.09% this year and recently decreased -0.21% or -$0.1 to settle at $46.78. Apac...
Which of these 2 stocks can turn out to be absolut... The shares of, Inc. have increased by more than 12.02% this year alone. The shares recently went down by -0.45% or -$0.21 and now trades at $46...
Taking Tally Of Helios and Matheson Analytics Inc.... The shares of Helios and Matheson Analytics Inc. have increased by more than 176.67% this year alone. The shares recently went up by 8.05% or $0.68 an...
Synchrony Financial (SYF) is better stock pick tha... The shares of Facebook, Inc. have decreased by more than -11.53% this year alone. The shares recently went up by 0.46% or $0.72 and now trades at $156...